The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients

Sponsor
Netherlands Open University (Other)
Overall Status
Completed
CT.gov ID
NCT00859768
Collaborator
Dutch Cancer Society (Other), Maastricht University Medical Center (Other), Institute Verbeeten (Other), Maastro Clinic, The Netherlands (Other)
568
1
4
30
18.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effectiveness and feasibility of the Screening Inventory of Psychosocial Problems (SIPP) in consultation settings with respect to early recognition and treatment of psychosocial distress, communication between patients and physicians, and psychological distress and quality of life in cancer patients treated with radiotherapy (RT).

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire administration
N/A

Detailed Description

Background: The Screening Inventory of Psychosocial Problems (SIPP) is a short, validated self-administered questionnaire to identify psychosocial problems in cancer patients. The one page 24-item questionnaire assesses physical complaints, psychological complaints, and social and sexual problems. There is very little known about the effectiveness of using the SIPP in consultation settings.

Aim: The aim of this study is to test the hypothesis that using the SIPP may prevent underdiagnosis of early symptoms reflecting psychosocial problems, should facilitate communication between physicians and patients about psychosocial distress and may contribute to adequate referral to relevant psychosocial caregivers.

Methods: A Cluster Randomized Controlled Trail (CRCT) is developed using a Solomon four-group design (two intervention and two control groups) to evaluate the effects of using the SIPP. Radiotherapists instead of patients are at random allocated to experimental or control groups. All included patients are randomized into the groups with and without pre-measurement. Psychosocial distress, quality of life, patients' satisfaction about communication with their radiotherapist during first consultation and the number and type of referred patients to psychosocial caregivers are assessed. Self-administered assessments are conducted at four times: pre-test before first consultation (T1), and post-tests directly following the first consultation (T2), three months (T3) and one year after (T4) the first measurement. Medical information are gathered from patients' medical records. Furthermore, a process evaluation is carried out.

Relevance: Using the SIPP may lead to a reduction of psychosocial problems and better quality of life, both on the short and long term. If the SIPP proves to be effective, the results of this project may contribute to motivate health care workers to use the SIPP as a standard method for early detection of psychosocial distress in oncology departments in the Netherlands and abroad.

Study Design

Study Type:
Interventional
Actual Enrollment :
568 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients Treated With Radiotherapy.
Study Start Date :
Apr 1, 2008
Actual Primary Completion Date :
Oct 1, 2010
Actual Study Completion Date :
Oct 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group 1

Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.

Other: Questionnaire administration
The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
Other Names:
  • Psychosocial assessment
  • Screening
  • Experimental: Intervention group 2

    No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.

    Other: Questionnaire administration
    The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
    Other Names:
  • Psychosocial assessment
  • Screening
  • No Intervention: Control group 1

    Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.

    No Intervention: Control group 2

    No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.

    Outcome Measures

    Primary Outcome Measures

    1. The primary effect outcome measurement is the number and type of referred patients with psychosocial problems to psychosocial caregivers and type of referrals with respect to psychosocial problems. [Is measured at three (T3) and twelve (T4) months after first measurement]

    Secondary Outcome Measures

    1. The secondary outcome measurements are patients' satisfaction with the radiotherapist-patient communication, psychosocial distress and quality of life. [Patients' satisfaction with the radiotherapist-patient communication is measured after first consultation with radiotherapist (T2) and psychosocial distress and quality of life is measured at three (T3) and twelve months (T4) after first measurement.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Breast Cancer

    • Lung Cancer

    • Prostate cancer

    • Bladder Cancer

    • Colorectal Cancer

    • Cervix Cancer

    • Cancer of endometrium

    • Cancer of Skin

    • Hodgkin Lymphoma

    • Non-Hodgkin Lymphoma

    • Must receive radiotherapy treatment (RT)

    • 18 years of age or older

    Exclusion Criteria:
    • Metastases

    • Less than 10 fractions of radiotherapy treatment (RT)

    • Unable to read, and speak Dutch

    • Unable to complete questionnaires

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institute Verbeeten Tilburg Brabant Netherlands 5042 SB

    Sponsors and Collaborators

    • Netherlands Open University
    • Dutch Cancer Society
    • Maastricht University Medical Center
    • Institute Verbeeten
    • Maastro Clinic, The Netherlands

    Investigators

    • Principal Investigator: Lilian Lechner, PhD, Netherlands Open University, Faculty of Psychology
    • Principal Investigator: Gertrudis I Kempen, PhD, Maastricht University, Faculty of Health, Medicine, and life Sciences, Department of Health Care and Nursing Science, School for Public Health and Primary Care (CAPHRI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00859768
    Other Study ID Numbers:
    • MB254
    • Dutch Cancer Society
    First Posted:
    Mar 11, 2009
    Last Update Posted:
    Mar 8, 2011
    Last Verified:
    Mar 1, 2009
    Keywords provided by , ,
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 8, 2011